The two Fs

Better late than never.

Novartis's press release may have been a month after filing the NDA for Fingolimod with the FDA, but it was before something else:

With all the excitement surrounding the imminent Fampridine-SR or Ampyra (Acorda) PDUFA on January 22nd, 2010, Novartis may have used the quiet before the storm of Ampyra to excite analysts and investors about its own big (no, HUGE) news.

Or, maybe it was the JPMorgan Healthcare Conference and the NEJM.

- Dr. Daniel Kantor, MD BSE
Medical Director
Neurologique

info@neurologique.org
www.neurologique.org